MedTrace Logo

TDM Guided Early Optimization of ADAL in Crohn's Disease

NCT03261102 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2025-05-25

No results posted yet for this study

Summary

To investigate the influence of early therapeutic drug monitoring and dose optimization on disease outcome in Crohn's patients treated with Adalimumab.

Conditions

  • Crohn Disease
  • Drug Monitoring
  • Inflammatory Bowel Diseases

Interventions

BIOLOGICAL

Adalimumab

Sponsors & Collaborators

  • AbbVie

    collaborator INDUSTRY

  • waqqas.afif

    lead OTHER

Principal Investigators

  • Waqqas Afif, MD, FRCPC · McGill University Health Centre/Research Institute of the McGill University Health Centre

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-01-17
Primary Completion
2025-01-15
Completion
2025-06-01

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03261102 on ClinicalTrials.gov